11/24/2024

Janusmed sex and gender

Janusmed sex and gender – Sotalol

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Sotalol

Sotalol

Class : C

Show all info

Print

Contact us

  1. Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol. 1997;37:799-809.

  2. Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2014;77(3):522-31.

  3. Sotacor (sotalol). Summary of Product Charateristics. Swedish Medical Products Agency [updated 2018-09-30, cited 2019-05-16].

  4. Suttorp MJ, Kingma JH, Peels HO, Koomen EM, Tijssen JG, van Hemel NM et al. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol. 1991;68:1163-9.

  5. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?. Am J Cardiol. 1998;81:869-76.

  6. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.

  7. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-7.

  8. Yarnoz MJ, Curtis AB. More reasons why men and women are not the same (gender differences in electrophysiology and arrhythmias). Am J Cardiol. 2008;101:1291-6.

  9. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2535-41.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]

  1. Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol. 1997;37:799-809.
  2. Darpo B, Karnad DR, Badilini F, Florian J, Garnett CE, Kothari S et al. Are women more susceptible than men to drug-induced QT prolongation? Concentration-QTc modelling in a phase 1 study with oral rac-sotalol. Br J Clin Pharmacol. 2014;77(3):522-31.
  3. Sotacor (sotalol). Summary of Product Charateristics. Swedish Medical Products Agency [updated 2018-09-30, cited 2019-05-16].
  4. Suttorp MJ, Kingma JH, Peels HO, Koomen EM, Tijssen JG, van Hemel NM et al. Effectiveness of sotalol in preventing supraventricular tachyarrhythmias shortly after coronary artery bypass grafting. Am J Cardiol. 1991;68:1163-9.
  5. Pratt CM, Camm AJ, Cooper W, Friedman PL, MacNeil DJ, Moulton KM et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die?. Am J Cardiol. 1998;81:869-76.
  6. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91:39D-44D.
  7. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-7.
  8. Yarnoz MJ, Curtis AB. More reasons why men and women are not the same (gender differences in electrophysiology and arrhythmias). Am J Cardiol. 2008;101:1291-6.
  9. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2535-41.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.]